DOCSLIB.ORG

Neurimminfl2018018622 1..3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurimminfl2018018622 1..3 Volume 6, Number 2, March 2019 Neurology.org/NN A peer-reviewed clinical and translational neurology open access journal CLINICAL/SCIENTIFIC NOTE Balint syndrome in anti-NMDA receptor encephalitis e532 ARTICLE Real-world validation of the 2017 McDonald criteria for pediatric MS e528 ARTICLE HIV is associated with endothelial activation despite ART, in a sub-Saharan African sett ing e531 ARTICLE Mouse model of anti-NMDA receptor post–herpes simplex encephalitis e529 Academy Officers Neurology® is a registered trademark of the American Academy of Neurology (registration valid in the United States). Ralph L. Sacco, MD, MS, FAAN, President Neurology® Neuroimmunology & Neuroinflammation (eISSN 2332-7812) is an James C. Stevens, MD, FAAN, President Elect open access journal published online for the American Academy of Neurology, Ann H. Tilton, MD, FAAN, Vice President 201 Chicago Ave, Minneapolis, MN 55415, by Wolters Kluwer Health, Inc. at 14700 Citicorp Drive, Bldg 3, Hagerstown, MD 21742. Business offices are Carlayne E. Jackson, MD, FAAN, Secretary located at Two Commerce Square, 2001 Market St., Philadelphia, PA 19103. Production offices are located at 351 West Camden Street, Baltimore, MD Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, Treasurer 21201-2436. © 2019 American Academy of Neurology. Terrence L. Cascino, MD, FAAN, Past President Neurology® Neuroimmunology & Neuroinflammation is an official journal of the American Academy of Neurology. Journal website: Neurology.org/NN, AAN website: AAN.com Executive Office, American Academy of Neurology Copyright and Permission Information: Please go to the journal website Catherine M. Rydell, CAE, Executive Director/CEO (www.neurology.org/nn) and click the Permissions tab for the relevant article. 201 Chicago Ave Alternatively, send an email to [email protected]. General information about permissions can be found here: https://www.lww.com/ Minneapolis, MN 55415 journal-permission. Tel: 612-928-6100 Disclaimer: Opinions expressed by the authors and advertisers are not necessarily those of the American Academy of Neurology, its affiliates, or of the Publisher. The American Academy of Neurology, its affiliates, and the Editorial Office Publisher disclaim any liability to any party for the accuracy, completeness, efficacy, or availability of the material contained in this publication (including Patricia K. Baskin, MS, Executive Editor drug dosages) or for any damages arising out of the use or non-use of any of the Kathleen M. Pieper, Senior Managing Editor, Neurology material contained in this publication. Sharon L. Quimby, Managing Editor, Neurology® Clinical Practice Advertising Sales Representatives: Wolters Kluwer, 333 Seventh Avenue, New York, NY 10001. Contacts: Eileen Henry, tel: 732-778-2261, fax: 973-215-2485, Morgan S. Sorenson, Managing Editor, Neurology® Neuroimmunology [email protected] and in Europe: Craig Silver, tel: +44 7855 & Neuroinflammation 062 550 or e-mail: [email protected]. ff Careers & Events: Monique McLaughlin, Wolters Kluwer, Two Commerce Lee Ann Kle man, Managing Editor, Neurology® Genetics Square, 2001 Market Street, Philadelphia, PA 19103, tel: (215)-521- 8468, fax: Andrea R. Rahkola, Production Editor, Neurology 215-521-8801; [email protected]. Robert J. Witherow, Senior Editorial Associate Reprints: Meredith Edelman, Commercial Reprint Sales, Wolters Kluwer, Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103, tel: Karen Skaja, Senior Editorial Associate 215-356-2721; [email protected]; reprintsolutions@ Kaitlyn Aman Ramm, Editorial Assistant wolterskluwer.com. Kristen Swendsrud, Editorial Assistant Special projects: US & Canada: Alan Moore, Wolters Kluwer, Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103, tel: 215-521-8638, Justin Daugherty, Editorial Assistant [email protected]. International: Andrew Wible, Senior Manager, Rights, Licensing, and Partnerships, Wolters Kluwer, translationrights@ wolterskluwer.com. Publisher Wolters Kluwer Baltimore, MD Publishing Staff Kim Jansen, Executive Publisher Jessica Heise, Production Team Leader, Neurology Journals Megen Miller, Production Editor Stacy Drossner, Production Associate A peer-reviewed clinical and translational neurology open access journal Neurology.org/NN Neurology® Neuroimmunology & Neuroinflammation Editor JosepO.Dalmau,MD,PhD Vision Neurology® Neuroimmunology & Neuroinflammation will be the premier peer- Deputy Editor reviewed journal for experts in the fields of Scott S. Zamvil, MD, PhD, FAAN neuroimmunology and neuroinflammation. Associate Editors Michael Heneka, MD Mission Neurology: Neuroimmunology & Dennis Kolson, MD, PhD Neuroinflammation will provide neurologists Friedmann Paul, MD with peer-reviewed articles, editorials, and reviews to enhance patient care, education, Editorial Board and clinical & translational research. Rohit Aggarwal, MD, MS Jun Li, MD, PhD Sergio E. Baranzini, PhD Lin Mei, MD, PhD Susanne Benseler, MD Andrew McKeon, MD Editorial ff Tel: 612-928-6400 Je rey L. Bennett, MD, PhD, FAAN Christopher Power, MD Inquiries Toll-free: 800-957-3182 (US) S´everine Boill´ee, PhD Richard M. Ransohoff,MD Matthijs C. Brouwer, MD, PhD Christine Stadelmann, MD Fax: 612-454-2748 Wolfgang Br¨uck, MD Israel Steiner, MD [email protected] David B. Clifford, MD, FAAN Lawrence Steinman, MD Russell C. Dale, MBChB, MRCP, PhD Jesper Tegn´er, PhD, MSc Oscar H. Del Brutto, MD, FAAN Silvia N. Tenembaum, MD Stay facebook.com/NeurologyNN Thomas G. Forsthuber, MD Maarten J. Titulaer, MD, PhD Connected Kazuo Fujihara, MD Ari Waisman, PhD twitter.com/greenjournal ff Je rey M. Gelfand, MD, MAS, FAAN Hugh J. Willison, MBBS, PhD youtube.com/user/NeurologyJournal Joseph El Khoury, MD Gregory F. Wu, MD, PhD Markus P. Kummer, PhD Neurology® Journals Editor-in-Chief Classification of Evidence Review Team Robert A. Gross, MD, PhD, FAAN Melissa J. Armstrong, MD Richard L. Barbano, MD, PhD, FAAN Deputy Editor Richard M. Dubinsky, MD, MPH, FAAN Bradford B. Worrall, MD, MSc, FAAN Jeffrey J. Fletcher, MD, MSc Gary M. Franklin, MD, MPH, FAAN Section Editors David S. Gloss II, MD, MPH&TM John J. Halperin, MD, FAAN Biostatistics Jason Lazarou, MSc, MD Richard J. Kryscio, PhD Steven R. Mess´e, MD, FAAN Christopher A. Beck, PhD Pushpa Narayanaswami, MBBS, DM, FAAN Sue Leurgans, PhD Alex Rae-Grant, MD Classification of Evidence Evaluations Gary S. Gronseth, MD, FAAN Podcasts Stacey L. Clardy, MD, PhD Jeffrey B. Ratliff, MD, Deputy Podcast Editor Ombudsman David S. Knopman, MD, FAAN Scientific Integrity Advisor Robert B. Daroff, MD, FAAN TABLE OF CONTENTS Volume 6, Number 2, March 2019 Neurology.org/NN Articles e538 Anti-MOG encephalitis mimicking small vessel CNS vasculitis K. Patterson, E. Iglesias, M. Nasrallah, V. Gonz´alez-Alvarez,´ M. Suñol, J. Anton, A. Saiz, E. Lancaster, and T. Armangue Open Access Editorial, p. e544 e528 Real-world validation of the 2017 McDonald criteria for pediatric MS Y.Y.M. Wong, C.L. de Mol, R.M. van der Vuurst de Vries, E.D. van Pelt, I.A. Ketelslegers, C.E. Catsman-Berrevoets, R.F. Neuteboom, and R.Q. Hintzen, On behalf of the Dutch pediatric MS and ADEM study group Open Access Class of Evidence e529 Mouse model of anti-NMDA receptor post–herpes simplex encephalitis J. Linnoila, B. Pulli, T. Armangu´e, J. Planagum`a, R. Narsimhan, S. Schob, M.W.G. Zeller, J. Dalmau, and J. Chen Open Access e530 MRI phenotypes in MS: Longitudinal changes and miRNA signatures C.C. Hemond, B.C. Healy, S. Tauhid, M.A. Mazzola, F.J. Quintana, R. Gandhi, H.L. Weiner, and R. Bakshi Open Access e531 HIV is associated with endothelial activation despite ART, in a sub-Saharan African setting J. Kamtchum-Tatuene, H. Mwandumba, Z. Al-Bayati, J. Flatley, M. Griffiths, T. Solomon, and L. Benjamin Open Access e535 Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology N. Uchio, K. Taira, C. Ikenaga, M. Kadoya, A. Unuma, K. Yoshida, S. Nakatani-Enomoto, Y. Hatanaka, Y. Sakurai, Y. Shiio, K. Kaida, A. Kubota, T. Toda, and J. Shimizu Editor’s Corner Open Access e543 Cranial nerve involvement in patients with MOG e540 Rectifying neurologic diagnosis through – autoantibodies antibody associated disease A. Cobo-Calvo, X. Ayrignac, P. Kerschen, P. Horellou, F. Cotton, J. Dalmau P. Labauge, S. Vukusic, K. Deiva, C. Serguera, and R. Marignier Open Access Open Access Editorial Clinical/Scientific Notes e544 Diagnostic challenges and pitfalls of myelin e533 pRNFL as a marker of disability worsening in the – oligodendrocyte glycoprotein antibody associated medium/long term in patients with MS demyelination: Lessons from neuropathology C. Cordano, B. Nourbakhsh, M. Devereux, V. Damotte, D. Bennett, R. Hoftberger¨ and E. Gelpi S.L. Hauser, B.A.C. Cree, J.M. Gelfand, and A.J. Green Open Access Companion article, p. e538 Open Access Continued TABLE OF CONTENTS Volume 6, Number 2, March 2019 Neurology.org/NN e536 Episodic ataxia in CASPR2 autoimmunity A.S. Lopez´ Chiriboga and S. Pittock Open Access Video e537 Anti-NMDAR encephalitis with concomitant varicella zoster virus detection and nonteratomatous malignancy P.A. Prakash, J. Jin, K. Matharu, T. Garg, W.C. Tsai, P. Patel, J.E. Weatherhead, and J.S. Kass Open Access Cover image e539 A fatal case of daclizumab-induced liver failure in a Pathologic findings included infiltrates of T and B lymphocytes in patient with MS association with edema, perivascular demyelination, and reactive gliosis M. Stettner, C.C. Gross, A.K. Mausberg, R. Pul, A. Junker, H.A.
Load more

Recommended publications
  • CORRECTED Aston Phd Thesis
    Community-acquired pneumonia in Malawian adults: Aetiology and predictors of mortality. Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor of Philosophy Stephen James Aston MBChB, BMedSc, MRCP, DTMH August 2016 Declaration I declare that this thesis was composed by me and that the work contained therein is my own, except where explicitly stated otherwise in the text. Any contribution of others is described briefly below and in detail at the beginning of relevant chapters. The work within this thesis has not been submitted in whole or in part for any other degree or professional qualification. My supervisors Professor Stephen Gordon (Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), Malawi) Professor Robert Heyderman (University College London, UK) and Dr Henry Mwandumba (MLW) provided advice on all aspects of the design, conduct and analysis of the research presented here. Professor Paul Garner (Liverpool School of Tropical Medicine, UK) advised on the methodology and analysis of the systematic review presented in chapter 2. Professor Charles Feldman (University of Witwatersrand, South Africa) independently reviewed all titles and corroborated study selection. Victoria Lutje (search strategist) advised on the search strategy and performed the database searches. The Malawian adult lower respiratory tract infection severity, aetiology and outcome (MARISO) study presented in chapters 3, 4 and 5 was one of several concurrently recruiting adult respiratory infection projects based at MLW and Queen Elizabeth Central Hospital (QECH), Malawi. Recruitment to the MARISO study was nested within that of the Burden and Severity of HIV-associated Influenza (BASH-FLU) Study (Principal Investigator: Dr Antonia Ho) and integrated with that of the existing severe acute respiratory infection surveillance programme (Principal Investigators: Dr Dean Everett and Dr Ingrid Peterson).
    [Show full text]
  • Consensus Statement on Immune Modulation in Multiple Sclerosis
    [Downloaded free from http://www.annalsofian.org on Monday, June 8, 2020, IP: 202.164.42.67] View Point Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID‑19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology Rohit Bhatia, M. V. Padma Srivastava, Dheeraj Khurana1, Lekha Pandit2, Thomas Mathew3, Salil Gupta4, Netravathi M5, Sruthi S. Nair6, Gagandeep Singh7, Bhim S. Singhal8 Department of Neurology, All India Institute of Medical Sciences, New Delhi, 1Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, 2Department of Neurology, K.S. Hegde Medical Academy, Mangalore, Karnataka, 3Department of Neurology, St John’s Medical College, Bangalore, Karnataka, 4Department of Neurology, Command Hospital Air Force, Bangalore, Karnataka, 5Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, 6Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, 7Department of Neurology, Dayanand Medical College and Hospital, Ludhiana, Punjab, 8Department of Neurology, Bombay Hospital, Mumbai, Maharashtra, India Abstract Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic. Keywords: COVID 19, disease modifying therapy, immunotherapy, MOG, MS, NMOSD INTRODUCTION cough, myalgia and headache with acute respiratory distress syndrome (ARDS) being the most frequent complication, In December 2019, health authorities recognized an outbreak inducing mortality in six (15%) patients.
    [Show full text]
  • SERIES #3 Mlet's Gaoin Gmentum a Collaborative Series Brought to You by the Sumaira Foundation for NMO and the MOG Project ACUTE VS
    SERIES #3 MLet's gaOin Gmentum a collaborative series brought to you by The Sumaira Foundation for NMO and The MOG Project ACUTE VS. PREVENTIVE TREATMENTS: What's the difference? ACUTE PREVENTATIVE Acute attacks are suspected when Long-term treatment focused on symptoms last 24 hours or more. modification of the immune system to Medical tests are used to confirm the prevent relapses. attack. To limit overtreatment: usually Short-term treatment focused on recommend to hold preventive therapy to decreasing inflammation (steroids) and recurrent disease (but may consider it antibody removal (IVIG, PLEX). after a single severe attack). Typically started immediately after initial Many patients are on preventive presentation to avoid long-term damage. medications for years. Duration of treatment should be individualized to each patient. MOG antibody titers can decrease with treatment but this may not indicate monophasic disease. The link between MOG antibody titers, treatment and recurring relapses remains uncertain. COMMON TREATMENTS FOR MOG-AD IV STEROIDS S T N E M T A E ORAL R T IVIG A E STEROIDS T U C A PLEX COMMON TREATMENTS FOR MOG-AD S T IVIG N E M T A E R T E azathioprine V mycophenolate I T (CellCept) P (Imuran) A T N E V E R P rituximab (Rituxan) INTRAVENOUS (IV) STEROIDS (METHYLPREDNISOLONE) Acute Treatments HOW IT WORKS WHAT TO EXPECT Part of the drug class corticosteroids. In some cases, patients will be hospitalized for the course of their Acts as an anti-inflammatory agent to treatment, others receive infusion via outpatient services. slow the body’s response to injury or Can address symptoms as early as 2-3 days however recovery disease, including reducing swelling from damage varies.
    [Show full text]
  • Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody
    Review Article Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody Jonathan D. Santoro1,2,3,4 Tanuja Chitnis1,2 1 Department of Neurology, Massachusetts General Hospital, Boston, Address for correspondence Jonathan D. Santoro, MD, Department of Massachusetts, United States Neurology, Massachusetts General Hospital, 55 Fruit Street, ACC 708, 2 Department of Neurology, Harvard Medical School, Boston, Boston, MA 02114, United States (e-mail: [email protected]). Massachusetts, United States 3 Department of Neurology, Children’s Hospital of Los Angeles, Los Angeles, California, United States 4 Keck School of Medicine, University of Southern California, Los Angeles, California, United States Neuropediatrics Abstract Acute disseminated encephalomyelitis (ADEM) is a common yet clinically heterogenous syndrome characterized by encephalopathy, focal neurologic findings, and abnormal Keywords neuroimaging. Differentiating ADEM from other demyelinating disorders of childhood ► ADEM can be difficult and appropriate interpretation of the historical, clinical, and neurodiag- ► acute disseminated nostic components of a patient’s presentation is critical. Myelin oligodendrocyte glycopro- encephalomyelitis tein (MOG) antibody-associated diseases are a recently recognized set of disorders, which ► diagnosis include ADEM presentations, among other phenotypes. This review article discusses the ► treatment clinical diagnosis, differential diagnosis, interpretation of data, and treatment/prognosis of ► MOG antibody this unique syndrome with distinctive review of the spectrum of MOG antibodies. Introduction activated T cells recruits additional immune cells to the CNS leading to primary injury of white matter.7 Although more Acute disseminated encephalomyelitis (ADEM) is an immune- nuanced than described, for the scope of this review, the mediated disorder of the central nervous system (CNS), affect- authors will focus on the clinical aspects of the disease and ing both children and adults.
    [Show full text]
  • MOG Antibody Positive Optic Perineuritis: an Observational Study in Han Chinese
    MOG Antibody Positive Optic Perineuritis: an Observational Study in Han Chinese CHAO MENG Beijing Tongren Hospital https://orcid.org/0000-0002-9011-6693 Jia-wei Wang Beijing Tongren Hospital Lei Liu Beijing Tongren Hospital Wen-jing Wei Beijing Tongren Hospital Jian-hua Tao Beijing Tongren Hospital Yong Li Beijing Tongren Hospital Qing-lin Yang Beijing Tongren Hospital Chun-tao Lai ( [email protected] ) Beijing Tongren Hospital, Capital Medical University https://orcid.org/0000-0002-4407-498X Research Keywords: Myelin oligodendrocyte glycoprotein (MOG), optic perineuritis, optic neuritis, magnetic resonance imaging, clinical features,epilepsy,meningitis,meningoencephalitis,prognosis Posted Date: March 16th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-266843/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/16 Abstract Objective To shed light on the clinical characteristics, magnet resonance imaging(MRI) changes, and prognosis of myelin oligodendrocyte glycoprotein antibody (MOG-IgG) positive OPN in Han Chinese. Methods We observed 39 MOG-IgG positive patients in our ward from January 1, 2017 , to December 31, 2019. Twenty patients met OPN inclusion criteria included contrast enhancement surrounding the optic nerve, and at least one of the following clinical symptoms: 1) reduction of visual acuity, 2) impairment of visual eld, and 3) eye pain. Single course group(n=11) and recurrence group(n=9) were used for comparison. Outcome variables included Wingerchuk visual acuity classication. Results Of the 20 patients with MOG-IgG positive OPN, 12(60%) were women. Ten cases (50%) presented with bilateral and 17 eyes (56.67%) with severe visual loss (SVL,≤ 0.1).
    [Show full text]
  • Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease
    MOG ANTIBODY DISEASE Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Encephalomyelitis WHAT IS MOG ANTIBODY-ASSOCIATED DEMYELINATION? Myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination is an immune-mediated inflammatory process that affects the central nervous system (brain and spinal cord). MOG is a protein that exists on the outer surface of cells that create myelin (an insulating layer around nerve fibers). In a small number of patients, an initial episode of inflammation due to MOG antibodies may be the first manifestation of multiple sclerosis (MS). Most patients may only experience one episode of inflammation, but repeated episodes of central nervous system demyelination can occur in some cases. WHAT ARE THE SYMPTOMS? • Optic neuritis (inflammation of the optic nerve(s)) may be a symptom of MOG antibody- associated demyelination, which may result in painful loss of vision in one or both eyes. • Transverse myelitis (inflammation of the spinal cord) may cause a variety of symptoms that include: o Abnormal sensations. Numbness, tingling, coldness or burning in the arms and/or legs. Some are especially sensitive to the light touch of clothing or to extreme heat or cold. You may feel as if something is tightly wrapping the skin of your chest, abdomen or legs. o Weakness in your arms or legs. Some people notice that they're stumbling or dragging one foot, or heaviness in the legs. Others may develop severe weakness or even total paralysis. o Bladder and bowel problems. This may include needing to urinate more frequently, urinary incontinence, difficulty urinating and constipation. • Acute disseminated encephalomyelitis (ADEM) may cause loss of vision, weakness, numbness, and loss of balance, and altered mental status.
    [Show full text]
  • Full Disclosures
    ARTICLE OPEN ACCESS Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases Kathrin Schanda, MSc, Patrick Peschl, PhD, Magdalena Lerch, MSc, Barbara Seebacher, PhD, Correspondence Swantje Mindorf, MSc, Nora Ritter, MSc, Monika Probst, PhD, Harald Hegen, MD, PhD, Dr. Reindl [email protected] Franziska Di Pauli, MD, PhD, Eva-Maria Wendel, MD, Christian Lechner, MD, Matthias Baumann, MD, Sara Mariotto, MD, PhD, Sergio Ferrari, MD, Albert Saiz, MD, PhD, Michael Farrell, MD, Maria Isabel S. Leite, MD, DPhil, Sarosh R. Irani, MD, DPhil, Jacqueline Palace, FRCP, DM, Andreas Lutterotti, MD, Tania Kumpfel,¨ MD, Sandra Vukusic, MD, Romain Marignier, MD, PhD, Patrick Waters, PhD, Kevin Rostasy, MD, Thomas Berger, MD, Christian Probst, PhD, Romana Hoftberger,¨ MD, and Markus Reindl, PhD Neurol Neuroimmunol Neuroinflamm 2021;8:e1027. doi:10.1212/NXI.0000000000001027 Abstract Objective To analyze serum immunoglobulin G (IgG) antibodies to major isoforms of myelin oligo- dendrocyte glycoprotein (MOG-alpha 1-3 and beta 1-3) in patients with inflammatory de- myelinating diseases. Methods Retrospective case-control study using 378 serum samples from patients with multiple sclerosis (MS), patients with non-MS demyelinating disease, and healthy controls with MOG alpha-1- IgG positive (n = 202) or negative serostatus (n = 176). Samples were analyzed for their reactivity to human, mouse, and rat MOG isoforms with and without mutations in the extra- cellular MOG Ig domain (MOG-ecIgD), soluble MOG-ecIgD, and myelin from multiple species using live cell-based, tissue immunofluorescence assays and ELISA. Results The strongest IgG reactivities were directed against the longest MOG isoforms alpha-1 (the currently used standard test for MOG-IgG) and beta-1, whereas the other isoforms were less frequently recognized.
    [Show full text]
  • Biomarkers in Rare Demyelinating Disease of the Central Nervous System
    International Journal of Molecular Sciences Review Biomarkers in Rare Demyelinating Disease of the Central Nervous System Marina Boziki , Styliani-Aggeliki Sintila, Panagiotis Ioannidis and Nikolaos Grigoriadis * 2nd Neurological University Department, Aristotle University of Thessaloniki, AHEPA General Hospital, 54634 Thessaloniki, Greece; [email protected] (M.B.); [email protected] (S.-A.S.); [email protected] (P.I.) * Correspondence: [email protected]; Tel.: +30-2310994683 Received: 14 October 2020; Accepted: 7 November 2020; Published: 9 November 2020 Abstract: Rare neurological diseases are a heterogeneous group corresponding approximately to 50% of all rare diseases. Neurologists are among the main specialists involved in their diagnostic investigation. At the moment, a consensus guideline on which neurologists may base clinical suspicion is not available. Moreover, neurologists need guidance with respect to screening investigations that may be performed. In this respect, biomarker research has emerged as a particularly active field due to its potential applications in clinical practice. With respect to autoimmune demyelinating diseases of the Central Nervous System (CNS), although these diseases occur in the frame of organ-specific autoimmunity, pathology of the disease itself is orchestrated among several anatomical and functional compartments. The differential diagnosis is broad and includes, but is not limited to, rare neurological diseases. Multiple Sclerosis (MS) needs to be differentially diagnosed from rare MS variants, Acute Disseminated Encephalomyelitis (ADEM), the range of Neuromyelitis Optica Spectrum Disorders (NMOSDs), Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease and other systemic inflammatory diseases. Diagnostic biomarkers may facilitate timely diagnosis and proper disease management, preventing disease exacerbation due to misdiagnosis and false treatment. In this review, we will describe advances in biomarker research with respect to rare neuroinflammatory disease of the CNS.
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorders
    Clinical Medicine 2019 Vol 19, No 2: 169–76 REVIEW N e u r o m y e l i t i s o p t i c a s p e c t r u m d i s o r d e r s Authors: S a i f H u d a , A D a n W h i t t a m , B M a n e e s h B h o j a k , C J a y n e C h a m b e r l a i n , D C a r m e l N o o n a n , E A n u J a c o b F , G a n d H R a c h e l K n e e n Neuromyelitis optica spectrum disorder (NMOSD) is an oedema from C1-T4 with contrast enhancement. His cerebrospinal uncommon antibody-mediated disease of the central nervous fluid demonstrated a lymphocytic pleocytosis (white cell count system. Long segments of spinal cord infl ammation (myelitis), 40 cells/mm 3 ) with normal protein, glucose ratio, and negative severe optic neuritis, and/or bouts of intractable vomiting and oligoclonal bands. Acute inflammatory transverse myelitis was hiccoughs (area postrema syndrome) are classic presentations diagnosed and he was given 1 gram of IV methylprednisolone for ABSTRACT of the disease and may alert the clinician to the diagnosis. 5 days. His serum was sent for aquaporin-4 (AQP4) and myelin Untreated, approximately 50% of NMOSD patients will be wheel- oligodendrocyte glycoprotein (MOG) antibodies (Abs).
    [Show full text]
  • Page 1 of 13 JOB DESCRIPTION POST Senior Clinical Lecturer in Infectious Diseases CONTRACT Permanent REFERENCE NO 510-18 REPORTS
    JOB DESCRIPTION POST Senior Clinical Lecturer in Infectious Diseases CONTRACT Permanent REFERENCE NO 510-18 REPORTS TO Head of Department of Clinical Sciences or International Public Health ROLE PURPOSE/SUMMARY The Senior Clinical Lecturer will collaborate with colleagues and existing portfolios of relevant research at LSTM to develop an applied health research programme (to include operational, implementation and health systems research) focused on lung health and tuberculosis in low- and middle-income countries at the Liverpool School of Tropical Medicine (LSTM). The post holder will combine clinical insights on TB care-seeking and treatment with other research disciplinary perspectives in order to bring innovation to LSTM’s growing portfolio of applied health research. The post will include responsibility for development and expansion of the tropical out-patient clinic at LSTM. SCOPE/BACKGROUND This is a strategically important post in expanding LSTM’s activities in health systems research and TB. The post is jointly funded by the NHS and will underpin and potentially ultimately lead the clinical activities of LSTM. In patient-clinical service provision will occur at the Tropical and Infectious Diseases Unit through an Honorary Consultant contract at the Royal Liverpool and Broadgreen University Hospitals NHS Trust; outpatient activity will be undertaken predominantly in the LSTM referral clinic. ROLE SPECIFIC RESPONSIBILITIES KEY KEY ACTIONS RESPONSIBILITIES These set out how the Key Responsibilities will be achieved 1 Research To
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes
    biomedicines Review Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes Marco A. Lana-Peixoto * and Natália Talim CIEM MS Research Center, Federal University of Minas Gerais Medical School, Belo Horizonte, MG 30130-090, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-31-32223935 Received: 20 May 2019; Accepted: 2 June 2019; Published: 12 June 2019 Abstract: Neuromyelitis optica spectrum disorder (NMOSD) and anti-myelin oligodendrocyte glycoprotein (anti-MOG) syndromes are immune-mediated inflammatory conditions of the central nervous system that frequently involve the optic nerves and the spinal cord. Because of their similar clinical manifestations and habitual relapsing course they are frequently confounded with multiple sclerosis (MS). Early and accurate diagnosis of these distinct conditions is relevant as they have different treatments. Some agents used for MS treatment may be deleterious to NMOSD. NMOSD is frequently associated with antibodies which target aquaporin-4 (AQP4), the most abundant water channel in the CNS, located in the astrocytic processes at the blood-brain barrier (BBB). On the other hand, anti-MOG syndromes result from damage to myelin oligodendrocyte glycoprotein (MOG), expressed on surfaces of oligodendrocytes and myelin sheaths. Acute transverse myelitis with longitudinally extensive lesion on spinal MRI is the most frequent inaugural manifestation of NMOSD, usually followed by optic neuritis. Other core clinical characteristics include area postrema syndrome, brainstem, diencephalic and cerebral symptoms that may be associated with typical MRI abnormalities. Acute disseminated encephalomyelitis and bilateral or recurrent optic neuritis are the most frequent anti-MOG syndromes in children and adults, respectively. Attacks are usually treated with steroids, and relapses prevention with immunosuppressive drugs.
    [Show full text]
  • CNS Inflammatory Vasculopathy with Antimyelin Oligodendrocyte Glycoprotein Antibodies in COVID-19
    CLINICAL/SCIENTIFIC NOTES OPEN ACCESS CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19 Ashwin A. Pinto, DPhil, FRCP, Liam S. Carroll, PhD, MRCP, Vijay Nar, MRCP, Aravinthan Varatharaj, MRCP, and Correspondence Ian Galea, PhD, FRCP Dr. Pinto [email protected] Neurol Neuroimmunol Neuroinflamm 2020;7:e813. doi:10.1212/NXI.0000000000000813 A 44-year-old right-handed woman reported a gradual onset of right hand incoordination seven MORE ONLINE days after the onset of minor respiratory symptoms and pruritus due to COVID-19 infection. Over 48 hours, the patient developed word-finding difficulties and progression in right arm COVID-19 Resources weakness leading to presentation to the emergency department as a suspected stroke. For the latest articles, invited commentaries, and Neurologic examination confirmed a mild expressive and receptive dysphasia, visual and sensory blogs from physicians inattention, and Medical Research Council grade 4/5 weakness in the right arm and right leg. around the world There was a rash on the chest wall bilaterally but no abnormal respiratory findings. NPub.org/COVID19 Blood workup confirmed normal results for full blood count (lymphocytes 1.5 × 109/L), C-reactive protein, lactate dehydrogenase, and ferritin. In addition, the blood tests for anti- nuclear antibody, antineutrophil cytoplasmic antibody, anticardiolipin immunoglobulin G and immunoglobulin M, lupus anticoagulant and cold agglutinins were negative. The HIV and syphilis serologies were also negative. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR from nasopharyngeal swab was positive. MRI of the head with gadolinium and magnetic resonance angiography at presentation showed T2-hyperintensity within the centrum semiovale bilaterally in a periventricular location, extending along the left temporal and occipital horns and into the subcortical deep white matter bilaterally, more extensive in the left hemisphere.
    [Show full text]